There in my bedroom, in the middle of the night, I saw my 11-year-old daughter clutching her ribs in agony. In the mad dash to hospital, I tried to stay calm, but I was full of fear and ...

Semaglutide, the active ingredient in Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist taken as a ...

New research finds that men taking a GLP-1 for their obesity or type 2 diabetes often experience a rise in testosterone ...

Would you get a one-time genetic modification such that you'd never have to take a GLP-1 drug for weight loss ever again?

Selena Gomez is making tongues wag with her latest social media post as fans are convinced she is using the famous weight ...

Ozempic (semaglutide) is a well-known prescription drug that’s used to treat the blood sugar of people with type 2 diabetes.

Semaglutide — the active ingredient in type 2 diabetes and weight-loss glucagon-like peptide-1 agonist ( GLP-1) medications Ozempic and Wegovy — may help lower dementia risk, a new study finds.

Pending a decision from the European Commission, Ozempic® (once-weekly semaglutide) will have the broadest approved label in the glucagon-like peptide-1 receptor agonist (GLP-1 RA) class ...

CHMP recommends approval of Novo Nordisk’s Ozempic for peripheral arterial disease Bagsværd, Denmark Wednesday, June 25, 2025, 15:00 Hrs [IST] Novo Nordisk, a leading global healthcare company, ...

Semaglutide (Ozempic) improves blood sugar control and weight loss in people with type 1 diabetes and obesity using insulin pumps, new study shows.

Novo Nordisk, a leading global healthcare company, announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for an ...